Editas Medicine, Inc. announced that James C. Mullen, the Executive Chairman of the Board of Directors notified the Board that he does not intend to seek re-election as a director of the Company when his current term ends at the 2023 Annual Meeting of Stockholders.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.325 USD | -1.93% | +2.13% | -47.57% |
05-30 | Evercore ISI Cuts Price Target on Editas Medicine to $7 From $15, Maintains In Line Rating | MT |
05-14 | Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.57% | 447M | |
+53.75% | 59.28B | |
+41.42% | 40.94B | |
-5.39% | 40.17B | |
-5.16% | 28.69B | |
+12.66% | 26.63B | |
-20.81% | 18.89B | |
+30.84% | 12.46B | |
+0.20% | 12.42B | |
+26.37% | 12.26B |
- Stock Market
- Equities
- EDIT Stock
- News Editas Medicine, Inc.
- Editas Medicine, Inc. Announces That James C. Mullen, the Executive Chairman of the Board of Directors Will Not Stand for Re-Election as A Director